For the year ending 2025-12-31, BIO had $42,400K increase in cash & cash equivalents over the period. $374,600K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Cash received from customers | 2,656,400 |
| Cash paid to suppliers and employees | 2,058,900 |
| Interest paid, net | 46,600 |
| Income tax payments, net | 61,600 |
| Dividend proceeds and miscellaneous receipts, net | 81,000 |
| (payments for) proceeds from forward foreign exchange contracts, net | -38,100 |
| Net cash provided by operating activities | 532,200 |
| Payments for purchases of property, plant and equipment | 157,600 |
| Proceeds from dispositions of property, plant and equipment | 100 |
| Proceeds from divestiture of a division | 0 |
| Payments for business acquisitions, net of cash received | 218,500 |
| Payments for acquired in-process research and development | 0 |
| Payments for purchases of marketable securities and investments | 669,300 |
| Proceeds from sales of marketable securities and investments | 793,600 |
| Proceeds from maturities of marketable securities and investments | 62,000 |
| Net cash (used in) provided by investing activities | -189,700 |
| Payments on long-term debt | 500 |
| Payments for debt issuance costs | 0 |
| Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options | 15,800 |
| Tax payments from net share settlement | 3,000 |
| Payments for purchases of treasury stock | 295,500 |
| Payments of contingent consideration | 0 |
| Net cash used in financing activities | -283,200 |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | -16,900 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 42,400 |
| Cash and cash equivalents at beginning of period | 489,800 |
| Cash and cash equivalents at end of period | 532,200 |
BIO-RAD LABORATORIES, INC. (BIO)
BIO-RAD LABORATORIES, INC. (BIO)